Pnd66 - Cost Effectiveness Analysis of Alemtuzumab as a Treatment Option for Patients With Multiple Sclerosis in Cyprus
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2032
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV